GSK's Crohn's disease treatment fails in Phase III trial

LONDON Fri Aug 23, 2013 10:46am EDT

The signage for the GlaxoSmithKline building is pictured in Hounslow, west London June 18, 2013. REUTERS/Luke MacGregor

The signage for the GlaxoSmithKline building is pictured in Hounslow, west London June 18, 2013.

Credit: Reuters/Luke MacGregor

Related Topics

LONDON (Reuters) - British pharmaceutical group GlaxoSmithKline Plc said vercirnon, a drug it was developing to treat Crohn's disease and licensed from ChemoCentryx, had failed in a late-stage clinical trial.

The medicine, which GSK licensed from the California-based company in 2010, did not improve the incidence of adverse events in patients when measured against a placebo, GSK said on Friday, and there was a trend for overall adverse events to increase as dosage levels increased.

The trial failure wiped as much as $242 million, or nearly half, from ChemoCentryx's value. Its shares were trading down 36 percent at $7.47 at 1438 GMT. GSK's shares were up 0.3 percent at 1,672 pence, underperforming a 0.7 percent stronger FTSE 100 index.

"The results from the SHIELD-1 study are clearly disappointing but we are committed to further explore the data to determine the way forward to help patients with this chronic debilitating gastrointestinal disease," said Paul-Peter Tak, senior vice president of GSK's immuno-inflammation research and development.

The company said new recruitment and dosing in the ongoing clinical trial had been suspended pending further review of the results.

Vercirnon, a type of drug called an antagonist, was being developed by GSK for the potential treatment of inflammatory bowel diseases, such Crohn's disease, a condition with symptoms such as persistent diarrhea and abdominal pain.

(Reporting by Paul Sandle; editing by David Evans)

FILED UNDER:
We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/
Comments (2)
inverse137 wrote:
“The results from the SHIELD-1 study are clearly disappointing but we are committed to further explore the data to determine the way forward to help patients with this chronic debilitating gastrointestinal disease,”

Yeah, that’s the line I knew would be in there.

Translation: Are product is worthless, we know it’s worthless, studies PROVE it is worthless, but we are going to try and lobby to get it passed so we can re-coup some of our money.

Aug 23, 2013 12:11pm EDT  --  Report as abuse
brutallyfrank wrote:
maybe crohn’s patients would benefit from a wheat-free diet like celiac patients do.

Aug 25, 2013 9:31pm EDT  --  Report as abuse
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.